IBD (inflammatory bowel disease) are associated with various types of joint manifestations, especially inflammatory. Patients with IBD treated with anti-TNF commonly report joint symptoms, with variable expressions and aetiologies, possibly responsible for impaired quality of life, and possibly leading to discontinuation of an effective and validated treatment.

Inclusion Criteria:

• Males or females over the age of 18 years at the time of inclusion
• Patients with IBD (Crohn's disease or ulcerative colitis), diagnosed by a set of compatible clinical (chronic diarrhoea, haematochezia, anoperineal lesions, etc.), laboratory, histological and endoscopic arguments. Patients will be included regardless of the severity of their disease, its clinical course, the type of lesions, and the presence or absence of associated manifestations.
• Patients treated with anti-TNF: infliximab or adalimumab.
• Informed patients not refusing to participate.
• Patients covered by French national health insurance.

Exclusion Criteria:

• Patients under the age of 18 years at the time of inclusion.
• Patients previously treated with anti-TNF, but no longer treated with anti-TNF at the time of inclusion.
• Protected majors (under permanent or temporary guardianship).

Patients with IBD (Crohn's disease or ulcerative colitis),